Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Renal Cell 7Sarcoma 5Melanoma 5Lymphoma, Non-Hodgkin 5Prostatic Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Endometrial Neoplasms 4Carcinoma, Hepatocellular 4Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Kidney Neoplasms 3Glioblastoma 3Squamous Cell Carcinoma of Head and Neck 2Rhabdomyosarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Lymphoma, Mantle-Cell 2Liver Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Congenital Abnormalities 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1

Interventions

Doxorubicin 6Trabectedin 5pazopanib 4Radiotherapy 4ribociclib 3pembrolizumab 3palbociclib 3Gemcitabine 3brostallicin 2Sunitinib 2Radiation Dose Hypofractionation 2Radiation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Immunoglobulin G 2Imatinib Mesylate 2Ifosfamide 2Docetaxel 2Dexamethasone 2CTLA-4 Antigen 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zimberelimab 1temsirolimus 1tanespimycin 1talimogene laherparepvec 1sotigalimab 1soblidotin 1sitravatinib 1saracatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Liposarcoma × temsirolimus × Clear all
NCT01614795 2018-12-11

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
46 enrolled 13 charts
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡